Claims for Patent: 8,105,634

Summary for Patent: 8,105,634

Title:	Umbilical cord biomaterial for medical use
Abstract:	The present invention provides a biomaterial comprising a mammalian umbilical cord membrane. The biomaterial can additionally comprise Wharton\'s jelly and/or one or more umbilical cord vessels. The biomaterial is preferably dry, and can be flat, tubular, or shaped to fit a particular body structure. The invention further provides laminates comprising at least one layer of an umbilical cord membrane biomaterial. The invention further provides methods of making the biomaterial, and laminates comprising the biomaterial, and methods of using the biomaterial.
Inventor(s):	Liu; Qing (Hillsborough, NJ), Rendon Barragan; Henry (Little Ferry, NJ), Matcham; George (Cranbury, NJ)
Assignee:	Anthrogenesis Corporation (Warren, NJ)
Application Number:	11/893,409
Patent Claims:	1. An umbilical cord-derived biomaterial comprising an isolated mammalian umbilical cord membrane, from which the vessels have been removed, and Wharton's jelly, wherein said biomaterial comprises less than 20% water by weight. 2. The biomaterial of claim 1 comprising an exogenous bioactive molecule. 3. The biomaterial of claim 2, wherein said bioactive molecule is a cytokine or a growth factor. 4. The biomaterial of claim 2, wherein said bioactive molecule is an extracellular matrix protein. 5. The biomaterial of claim 4, wherein said extracellular matrix protein is collagen, fibronectin, elastin, vitronectin, or hyaluronic acid. 6. The biomaterial of claim 2, wherein said bioactive molecule is hyaluronic acid. 7. The biomaterial of claim 6, wherein said hyaluronic acid is crosslinked to said umbilical cord membrane. 8. The biomaterial of claim 2, wherein the bioactive molecule is an antibiotic, a hormone, a growth factor, an anti-tumor agent, an anti-fungal agent, an anti-viral agent, a pain medication, an anti-histamine, an anti-inflammatory agent, an anti-infective agent, a wound healing agent, a wound sealant, a cellular attractant, a scaffolding reagent, or a small molecule. 9. The biomaterial of claim 8, further comprising a hydrogel composition. 10. The biomaterial of claim 1, comprising an exogenous polymer. 11. The biomaterial of claim 10, wherein said exogenous polymer is a synthetic biodegradable polymer or an anionic polymer. 12. An umbilical cord-derived biomaterial comprising an isolated mammalian umbilical cord membrane and Wharton's jelly, wherein said biomaterial comprises less than 20% by weight, and wherein the biomaterial is decellularized. 13. The biomaterial of claim 12, additionally comprising an exogenous stem cell. 14. An umbilical cord-derived biomaterial comprising an isolated mammalian umbilical cord membrane and Wharton's jelly, wherein said biomaterial comprises less than 20% water by weight, and wherein the biomaterial additionally comprising an exogenous stem cell. 15. The biomaterial of claim 14, wherein said exogenous stem cell is a placental stem cell, a mesenchymal stem cell, an embryonic stem cell, or a somatic stem cell. 16. The biomaterial of claim 15, wherein said somatic stem cell is a neural stem cell, a hepatic stem cell, a pancreatic stem cell, an endothelial stem cell, a cardiac stem cell, or a muscle stem cell. 17. A laminate comprising a plurality of layers, wherein at least one of the layers comprises an umbilical cord-derived biomaterial comprising an isolated mammalian umbilical cord membrane and Wharton's jelly, wherein said biomaterial comprises less than 20% water by weight. 18. A method of delivering a therapeutic agent to a subject comprising contacting the subject with the composition of claim 1, wherein said composition comprises a therapeutic agent.

Details for Patent 8,105,634

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2026-08-15